Pfizer Aktie News

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, both in combination wit...

The 6.7% dividend yield on offer from Pfizer (PFE -1.72%) is both a sign of opportunity and risk. A lot will happen over the next five years that will determine if that dividend is sustainable.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases. “IDWeek 2025 offers a critical opportunity to h...

Shares in IP Group PLC (LSE:IPO) rose 9% on Monday after investors welcomed the potential for future royalty income from Metsera, a biotech company that Pfizer has agreed to acquire for up to $7.3 billion. The agreement, announced in September, includes $4.9 billion in upfront cash and gives Pfizer control of Metsera's portfolio of next-generation obesity treatments.

IP Group PLC (LSE:IPO) could see future royalty income from a new wave of obesity drugs being developed by Metsera, a biotech company that Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed to buy for up to $7.3 billion. The deal, announced in late September, includes $4.9 billion in upfront cash and gives the US pharmaceutical giant control of a portfolio of next-generation obesity treatments.

Sometimes, things are going great for a stock with potentially more good news on the way. In other cases, things are going so badly for a stock that it almost has nowhere to go but up.

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deliver 23.93% to 38.57% net gains by October 2026, based on analyst targets. Stocks like CAG, VZ, DOC, BMY, KVUE, CPB, UDR, VTRS, KIM, TFC, KEY, HPQ, T, and RF meet the ideal of dividends from $1K inv...

Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.